Oculis Holding AG
$28.61
▼
-1.48%
2026-04-21 08:35:00
oculis.com
NGM: OCS
Explore Oculis Holding AG stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.64 B
Current Price
$28.61
52W High / Low
$30.68 / $16
Stock P/E
—
Book Value
$4.24
Dividend Yield
—
ROCE
-41%
ROE
-73.45%
Face Value
—
EPS
$-2.39
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
—
Beta
0.21
Debt / Equity
1.18
Current Ratio
5.96
Quick Ratio
5.96
Forward P/E
-12.81
Price / Sales
1,320.25
Enterprise Value
$1.37 B
EV / EBITDA
-16.83
EV / Revenue
1,144.52
Rating
Strong Buy
Target Price
$47.49
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Lite Strategy, Inc. | $1.19 | — | $42.54 M | 0% | -103.09% | -76.38% | $9 / $0.95 | $2.23 |
| 2. | ACADIA Pharmaceuticals Inc. | $22.09 | 9.63 | $3.77 B | — | 8.14% | 39.89% | $28.35 / $14.08 | $7.21 |
| 3. | Anavex Life Sciences Corp. | $3.65 | — | $338.25 M | — | -54.15% | -33.63% | $13.99 / $2.61 | $1.37 |
| 4. | Avalo Therapeutics, Inc. | $14.66 | — | $334.08 M | — | -70.45% | -72.44% | $20.72 / $3.39 | $4.49 |
| 5. | PharmaCyte Biotech, Inc. | $0.76 | — | $7.82 M | — | -8.38% | -8.24% | $1.51 / $0.63 | $3.59 |
| 6. | Protalix BioTherapeutics, Inc. | $2.27 | — | $184.11 M | — | -9.85% | -14.44% | $3.19 / $1.32 | $0.6 |
| 7. | Tenax Therapeutics, Inc. | $14.1 | — | $247.99 M | — | -58.09% | -55.64% | $18.38 / $4.63 | $2.29 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -20.63 M | -20.3 M | -20.77 M | -19.97 M | -17.26 M | — |
| Net Profit | -23.51 M | -16.86 M | -25.38 M | -33.21 M | -28.66 M | — |
| EPS in Rs | -0.41 | -0.29 | -0.44 | -0.57 | -0.49 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -81.67 M | -73.2 M | -45.85 M | -32.38 M |
| Net Profit | -98.96 M | -85.78 M | -88.8 M | -38.7 M |
| EPS in Rs | -1.71 | -1.48 | -1.53 | -0.67 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 235.96 M | 120.35 M | 114.35 M | 37.06 M |
| Total Liabilities | 39.89 M | 46.97 M | 20.62 M | 135.05 M |
| Equity | 196.07 M | 73.38 M | 93.73 M | -97.99 M |
| Current Assets | 218.89 M | 104.9 M | 101.02 M | 23.66 M |
| Current Liabilities | 36.75 M | 44.23 M | 19.09 M | 12.02 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -66.3 M | -48.92 M | -55.04 M | -25.07 M |
| Investing CF | -60.93 M | -16.08 M | -52.97 M | -3.55 M |
| Financing CF | 186.92 M | 53.98 M | 129.63 M | 1.71 M |
| Free CF | -67.69 M | -49.15 M | -55.09 M | -28.62 M |
| Capex | -1.39 M | -0.23 M | -0.05 M | -3.55 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -15.37% | 3.41% | -129.47% | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.